ArticleVeterinary research2026
Generation and epitope mapping of two distinct neutralizing mAb subsets targeting BVDV E2: a pan-pestivirus cross-reactive linear epitope and a BVDV-specific conformational epitope.
Article in Veterinary research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Bovine viral diarrhea virus (BVDV) is an important infectious pathogen responsible for substantial economic losses in the global cattle industry. The structural protein E2 serves as a major protective antigen of BVDV and is the main target for host neutralizing immune responses. However, its antigenic structure and epitope distribution remain poorly understood. Here, five novel monoclonal antibodies (mAbs) against the E2 protein of BVDV-1 were generated using hybridoma technology, and their reactivity patterns, biological properties, and recognized epitopes were systematically characterized. As a result, one mAb, TBH033, specifically reacted with BVDV, while four mAbs, TBH002, TBH004, TBH008, and TBH009, exhibited broad-spectrum reactivity against different subgenotypes of classical swine fever virus (CSFV) and BVDV, as well as E2 proteins from eight pestivirus species (BVDV-1, BVDV-2, BVDV-3, CSFV, BDV, PPeV, GPeV, and ovIT PeV). All five mAbs exhibited high binding affinity to the E2 protein and potent cross-neutralizing activity against BVDV strains of different subgenotypes. Epitope mapping with chimeric recombinant and site-mutated E2 proteins revealed that TBH002, TBH004, TBH008, and TBH009 recognized a linear epitope in the DA domain, comprising
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.